YTENQ — Yield10 Bioscience Share News
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.26m
- $0.06m
Tender Offer
Australia's Nufarm rises on obtaining commercial license from Yield10 Bioscience
Tender Offer
Brief: Yield10 Bioscience Announces Delisting from Nasdaq
Yield10 Bioscience Inc expected to post a loss of $2.64 a share - Earnings Preview
Yield10 Bioscience Inc reports results for the quarter ended in December - Earnings Summary
Yield10 Bioscience Inc expected to post a loss of 30 cents a share - Earnings Preview
Yield10 Bioscience Inc expected to post a loss of 30 cents a share - Earnings Preview
Yield10 Bioscience Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Yield10 Bioscience Provides An Update On Its Omega-3 Camelina Program
Brief: Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina
Brief: Yield10 Bioscience Exec Officers To Receive Payment Of Amount Of Salaries That Was Retained Pursuant To Amendments
Brief: USDA-Aphis Determines That Yield10 Bioscience’S Glufosinate Tolerant Camelina May Be Planted And Bred In The United States
Brief: Yield10 Bioscience Q3 Net Income USD -3.7 Million
Brief: Yield10 Bioscience Inc Signed A Non-Binding Letter Of Intent With Biomar Group
Brief: Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology
Yield10 rises on progress of herbicide-tolerant Camelina variety
Brief: Yield10 Bioscience Provides Update On Recent Advancements In The Development Of Elite Herbicide Tolerant Camelina
Brief: Yield10 Bioscience Completes Harvest Of A Majority Of The 2023 Winter And Spring Camelina Grain Grown Under Contract